Giuseppe Toffoli

Summary

Affiliation: Centro di Riferimento Oncologico
Country: Italy

Publications

  1. request reprint
    Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A. Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. Int J Biol Markers. 2003;18:218-21 pubmed
    ..These results indicate that MTHFR variants are not related to DLBCL development and MGMT hypermethylation...
  2. Dreussi E, Cecchin E, Polesel J, Canzonieri V, Agostini M, Boso C, et al. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. Int J Mol Sci. 2016;17: pubmed publisher
    ..073). This exploratory study highlighted new potential predictive biomarkers of neoadjuvant CRT and underlined the importance to strictly define treatment peculiarities in pharmacogenetic analyses. ..
  3. Pellizzoni E, Tommasini M, Marangon E, Rizzolio F, Saito G, Benedetti F, et al. Fluorescent molecularly imprinted nanogels for the detection of anticancer drugs in human plasma. Biosens Bioelectron. 2016;86:913-919 pubmed publisher
    ..The LOD was 400nM, with within-run variability <9%, day to day variability <5%, and good accuracy in the recovery of sunitinib from spiked samples. ..
  4. Giodini L, Re F, Campagnol D, Marangon E, Posocco B, Dreussi E, et al. Nanocarriers in cancer clinical practice: a pharmacokinetic issue. Nanomedicine. 2017;13:583-599 pubmed publisher
    ....
  5. Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, Polesel J, et al. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. Int J Mol Sci. 2017;18: pubmed publisher
    ..This exploratory study identified new HLA-G 3'UTR polymorphisms/haplotypes as potential predictive markers of G3-4 toxicities in CRC. ..
  6. request reprint
    Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-8 pubmed
    ..In particular, the possibility of a dose reduction for irinotecan in patients with a UGT1A1*28 polymorphism is not supported by the result of this analysis. ..
  7. request reprint
    Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 2007;22:S24-39 pubmed
    ....
  8. Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger C, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15:3550-6 pubmed publisher
    ..17-6.11). The study provides evidence supporting the association of MDM2 SNP309 with high-grade osteosarcoma risk in females and shows that TP53 Arg72Pro has a prognostic value for overall survival and EFS in osteosarcoma patients. ..
  9. Toffoli G, Cecchin E, Gasparini G, D Andrea M, Azzarello G, Basso U, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:866-71 pubmed publisher
    ..Prospective genotype-driven studies should test the efficacy of higher irinotecan doses in the FOLFIRI schedule. ..
  10. Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. Int J Mol Sci. 2017;18: pubmed publisher
    ....

Detail Information

Publications12

  1. request reprint
    Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A. Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. Int J Biol Markers. 2003;18:218-21 pubmed
    ..These results indicate that MTHFR variants are not related to DLBCL development and MGMT hypermethylation...
  2. Dreussi E, Cecchin E, Polesel J, Canzonieri V, Agostini M, Boso C, et al. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. Int J Mol Sci. 2016;17: pubmed publisher
    ..073). This exploratory study highlighted new potential predictive biomarkers of neoadjuvant CRT and underlined the importance to strictly define treatment peculiarities in pharmacogenetic analyses. ..
  3. Pellizzoni E, Tommasini M, Marangon E, Rizzolio F, Saito G, Benedetti F, et al. Fluorescent molecularly imprinted nanogels for the detection of anticancer drugs in human plasma. Biosens Bioelectron. 2016;86:913-919 pubmed publisher
    ..The LOD was 400nM, with within-run variability <9%, day to day variability <5%, and good accuracy in the recovery of sunitinib from spiked samples. ..
  4. Giodini L, Re F, Campagnol D, Marangon E, Posocco B, Dreussi E, et al. Nanocarriers in cancer clinical practice: a pharmacokinetic issue. Nanomedicine. 2017;13:583-599 pubmed publisher
    ....
  5. Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, Polesel J, et al. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. Int J Mol Sci. 2017;18: pubmed publisher
    ..This exploratory study identified new HLA-G 3'UTR polymorphisms/haplotypes as potential predictive markers of G3-4 toxicities in CRC. ..
  6. request reprint
    Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-8 pubmed
    ..In particular, the possibility of a dose reduction for irinotecan in patients with a UGT1A1*28 polymorphism is not supported by the result of this analysis. ..
  7. request reprint
    Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 2007;22:S24-39 pubmed
    ....
  8. Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger C, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15:3550-6 pubmed publisher
    ..17-6.11). The study provides evidence supporting the association of MDM2 SNP309 with high-grade osteosarcoma risk in females and shows that TP53 Arg72Pro has a prognostic value for overall survival and EFS in osteosarcoma patients. ..
  9. Toffoli G, Cecchin E, Gasparini G, D Andrea M, Azzarello G, Basso U, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:866-71 pubmed publisher
    ..Prospective genotype-driven studies should test the efficacy of higher irinotecan doses in the FOLFIRI schedule. ..
  10. Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. Int J Mol Sci. 2017;18: pubmed publisher
    ....
  11. Guida F, Battisti A, Gladich I, Buzzo M, Marangon E, Giodini L, et al. Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment. Biosens Bioelectron. 2018;100:298-303 pubmed publisher
    ..These results suggest that the in silico design of small artificial peptides is now a viable route for designing sensing units, opening a wide range of applications in diagnostic and clinical areas. ..
  12. De Mattia E, Cecchin E, Polesel J, Bignucolo A, Roncato R, Lupo F, et al. Genetic biomarkers for hepatocellular cancer risk in a caucasian population. World J Gastroenterol. 2017;23:6674-6684 pubmed publisher
    ..We identified five polymorphisms and interactions that contributed crucially to predicting HCC risk. These findings represented an important step towards improving HCC diagnosis and management. ..